Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval - Pulse 2.0

Pulse 2.0 · 2026-08-21

Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval Pulse 2.0

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.

Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。